Relative benefit ratios for SC to the pandemic influenza vaccine in healthy controls and disease controls compared with patients on anti-CD20 therapy
| Average duration of time since anti-CD20 therapy, mo . | No. of studies analyzed . | 1 dose (95% CI) . | I2 %, P . | 2 doses (95% CI) . | I2 %, P . | No. of studies analyzed . | 1 dose (95% CI) . | I2 %, P . | 2 doses (95% CI) . | I2 %, P . |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients on anti-CD20 therapy vs healthy controls | All patients on anti-CD20 therapy vs disease controls | |||||||||
| On active treatment, <3 | 1 | 0.05 (0-0.73) | N/A, 0.03 | — | — | 6 | 0.22 (0.09-0.56) | 3, .001 | 0.25 (0.12-0.55) | 0, .0006 |
| 3-6 | 1 | 0.50 (0.24-1.06) | N/A, 0.07 | — | — | 2 | 0.44 (0.23-0.84) | 0, .01 | 0.10 (0.01-1.49) | N/A, .10 |
| 6-12 | — | — | — | — | — | 1 | 0.77 (0.28-2.10) | N/A, .61 | 0.62 (0.23-1.67) | N/A, .35 |
| >12 | 1 | 0.50 (0.23-1.09) | N/A, 0.08 | 0.82 (0.51-1.32) | N/A, 0.41 | 1 | 1.03 (0.45-2.35) | N/A, .94 | 1.10 (0.74-1.63) | N/A, .65 |
| Only patients with hematologic malignancy on anti-CD20 therapy vs disease controls | ||||||||||
| On active treatment, <3 | 5 | 0.19 (0.06-0.61) | 21, .005 | 0.22 (0.09-0.52) | 0, .0007 | |||||
| 3-6 | 1 | 0.13 (0.01-1.85) | N/A, .13 | 0.10 (0.01-1.49) | N/A, .10 | |||||
| 6-12 | 1 | 0.77 (0.28-2.10) | N/A, .61 | 0.62 (0.23-1.67) | N/A, .35 | |||||
| >12 | 1 | 1.03 (0.45-2.35) | N/A, .94 | 1.10 (0.74-1.63) | N/A, .65 | |||||
| Average duration of time since anti-CD20 therapy, mo . | No. of studies analyzed . | 1 dose (95% CI) . | I2 %, P . | 2 doses (95% CI) . | I2 %, P . | No. of studies analyzed . | 1 dose (95% CI) . | I2 %, P . | 2 doses (95% CI) . | I2 %, P . |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients on anti-CD20 therapy vs healthy controls | All patients on anti-CD20 therapy vs disease controls | |||||||||
| On active treatment, <3 | 1 | 0.05 (0-0.73) | N/A, 0.03 | — | — | 6 | 0.22 (0.09-0.56) | 3, .001 | 0.25 (0.12-0.55) | 0, .0006 |
| 3-6 | 1 | 0.50 (0.24-1.06) | N/A, 0.07 | — | — | 2 | 0.44 (0.23-0.84) | 0, .01 | 0.10 (0.01-1.49) | N/A, .10 |
| 6-12 | — | — | — | — | — | 1 | 0.77 (0.28-2.10) | N/A, .61 | 0.62 (0.23-1.67) | N/A, .35 |
| >12 | 1 | 0.50 (0.23-1.09) | N/A, 0.08 | 0.82 (0.51-1.32) | N/A, 0.41 | 1 | 1.03 (0.45-2.35) | N/A, .94 | 1.10 (0.74-1.63) | N/A, .65 |
| Only patients with hematologic malignancy on anti-CD20 therapy vs disease controls | ||||||||||
| On active treatment, <3 | 5 | 0.19 (0.06-0.61) | 21, .005 | 0.22 (0.09-0.52) | 0, .0007 | |||||
| 3-6 | 1 | 0.13 (0.01-1.85) | N/A, .13 | 0.10 (0.01-1.49) | N/A, .10 | |||||
| 6-12 | 1 | 0.77 (0.28-2.10) | N/A, .61 | 0.62 (0.23-1.67) | N/A, .35 | |||||
| >12 | 1 | 1.03 (0.45-2.35) | N/A, .94 | 1.10 (0.74-1.63) | N/A, .65 | |||||
The RB is the ratio of SC rate in patients treated with anti-CD20 therapy to the SC rate in healthy or disease controls. Bold values represent statistically significant relative benefit ratios.
N/A, not applicable.
—, no available data.